Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Reynolds

Showing results (411-420 of 427) with videos related to

Pageof 43
Sort By:
American Journal of Respiratory and Critical Care Medicine|June 13, 2022
Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed TomographySimon L F Walsh, John A Mackintosh, Lucio Calandriello, et al.
The Medical Journal of Australia|February 2, 2018
Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summaryHelen E Jo, Jyotika D Prasad, Lauren K Troy, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Systemic inhibition of <i>de novo</i> purine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intakeJacob W Myers, Woo Yong Park, Alexander M Eddie, et al.
Respirology (Carlton, Vic.)|October 18, 2018
Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis RegistryHelen E Jo, Ian Glaspole, Nicole Goh, et al.
Thorax|September 24, 2024
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung diseaseAndrew Li, Alan Teoh, Lauren Troy, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Respirology (Carlton, Vic.)|November 24, 2020
Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New ZealandAdelle S Jee, Robert Sheehy, Peter Hopkins, et al.
The European Respiratory Journal|October 22, 2021
Biomarker signatures for progressive idiopathic pulmonary fibrosisBritt Clynick, Tamera J Corte, Helen E Jo, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
Pageof 43

Showing results (411-420 of 427) with videos related to

Sort By:
Pageof 43
American Journal of Respiratory and Critical Care Medicine|June 13, 2022
Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed TomographySimon L F Walsh, John A Mackintosh, Lucio Calandriello, et al.
The Medical Journal of Australia|February 2, 2018
Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summaryHelen E Jo, Jyotika D Prasad, Lauren K Troy, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Systemic inhibition of <i>de novo</i> purine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intakeJacob W Myers, Woo Yong Park, Alexander M Eddie, et al.
Respirology (Carlton, Vic.)|October 18, 2018
Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis RegistryHelen E Jo, Ian Glaspole, Nicole Goh, et al.
Thorax|September 24, 2024
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung diseaseAndrew Li, Alan Teoh, Lauren Troy, et al.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Respirology (Carlton, Vic.)|November 24, 2020
Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New ZealandAdelle S Jee, Robert Sheehy, Peter Hopkins, et al.
The European Respiratory Journal|October 22, 2021
Biomarker signatures for progressive idiopathic pulmonary fibrosisBritt Clynick, Tamera J Corte, Helen E Jo, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
Pageof 43